Genetic biomarkers are fixed from birth and offer a static view of what might happen. However, they miss real-time changes in the body as it responds to disease, lifestyle, environmental factors or ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.